Illumina, Inc.

ILMN · NASDAQ · USD

Analysis

Last 4 earnings calls · through Q2 FY2026

The NovaSeq X pricing squeeze is ending and clinical demand has taken over as the growth engine, which is why management raised its 2026 outlook twice. Research labs still aren't spending, and part of this year's instrument surge pays off only in 2027. Where inside Illumina's clinical growth is the momentum strongest?

  • Clinical sequencing became the entire growth story.

    Clinical consumables grew 15% ex-China in Q2 FY2026 and now make up about two-thirds of sequencing consumables revenue. Richer tests in oncology and rare disease read far more data per patient, so the same machine earns more. Are Illumina's clinical gains coming from more patients or richer tests?

  • Machines went out the door far faster than the plan.

    Management had targeted 50 to 60 NovaSeq X placements a quarter; the last two came in well above that. Customers take months to reach normal usage, so most of the added chemical revenue shows up in 2027, not this year.

  • Cost inflation is being absorbed, not passed on.

    Tariffs cut gross margin by about two points in Q3 and Q4 FY2025, and Q2 FY2026 brought higher memory and freight costs. Cost cuts, not price rises, covered them, so the extra revenue pays for costs rather than profit. How much of Illumina's 2026 margin plan assumes tariffs stay flat?

Bullish
  • Clinical keeps growing at the mid-teens rate management guides to. It is about two-thirds of the business now, so one healthy end market is enough to keep total sales rising.
  • The machines placed over the last three quarters fill up on schedule. Each one pulls through more than a million dollars of chemicals a year, so growth arrives without much new selling.
  • Research and academic funding finally loosens. Nothing new has to be invented for growth to jump, because those customers already own the machines.
Bearish
  • Research and academic budgets stay frozen into 2027. It is the one part of the business still shrinking every quarter, and it is where tomorrow's clinical tests are born.
  • Tariffs and memory-chip costs keep climbing. Management is paying for them with cost cuts rather than higher prices, and there is a limit to how many cuts are left.
  • Cheaper rival sequencers start winning clinical labs. Clinical is the only engine left, so share lost there slows the whole company, not just one piece of it.
PoliticiansInstitutionsInsiders
PoliticianTransactionAmountTradedFiled
Gilbert Ray Cisneros, Jr.
Democratic · House · CA-31
Purchase≥$1KFeb 10Mar 9
Ro Khanna
Democratic · House · CA-17
Sale≥$1KJan 29Feb 6
Lisa C. McClain
Republican · House · MI-9
Sale≥$1KOct 30Nov 21
Lisa C. McClain
Republican · House · MI-9
Sale≥$1KOct 31Nov 21
Lisa C. McClain
Republican · House · MI-9
Purchase≥$1KOct 30Nov 21

Congressional trading data provided by QuiverQuant

See all
Product segmentsGeography
FY2025 · USD

How Illumina turned $4.3B of revenue into $807.0M of operating income.

Revenue
Sequencing$4.0B
Microarray$358.0M
Total revenue$4.3B
Gross profit$2.9B66.1%
Operating income$807.0M18.6%
See all